Safety and Efficacy of Therapeutically Equivalent Doses of Sustained-Release Formulations of Isradipine and Felodipine
| Autor: | Michael B. Ganz, Brett A. Saksa |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Systole Diastole Blood Pressure Emergency Nursing Drug Substitution medicine Edema Humans Adverse effect Antihypertensive Agents Aged Ohio Isradipine Dose-Response Relationship Drug Felodipine business.industry Blood Pressure Monitoring Ambulatory Middle Aged Calcium Channel Blockers medicine.disease Surgery Treatment Outcome Blood pressure Heart failure Anesthesia Hypertension Emergency Medicine Ankle Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Congestive Heart Failure. 9:1-4 |
| ISSN: | 1751-7133 1527-5299 |
| DOI: | 10.1111/j.1527-5299.2003.03252.x |
| Popis: | This open-label, drug substitution study was conducted to determine if subjects receiving sustained-release isradipine (SR-I) can be safely switched to sustained-release felodipine (SR-F) and to assess whether SR-I provides better 24-hour blood pressure (BP) control than SR-F. Forty-one men receiving either SR-F 5 mg or SR-F 10 mg once daily for at least 6 months were switched to an equivalent dose of SR-I; BP was measured 2, 4, and 6 weeks after substitution. Significant reductions in systolic BP were seen in the SR-I 10 mg group after 4 weeks and they remained significantly lower through 6 weeks (p< or =0.05). Diastolic BP was reduced, but not significantly. After 6 weeks, SR-F therapy was reinstated, and BP returned toward baseline values. No serious adverse events were reported. SR-I can be safely substituted for SR-F and may provide better 24-hour control of BP than SR-F. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text